Forskolin (Colforsin)
别名: HL 362, Coleonol
中文名称:佛司可林
目录号:S2449 Purity: 99.06%
此产品请避光密封保存。
Forskolin (Colforsin)在各种各样细胞类型中,是一种普遍存在的真核细胞腺苷酸环化酶(AC)激活剂,在细胞生理学研究中,通常用来提高cAMP水平。Forskolin 还可激发 PXR 和 FXR的活性而诱导自噬。
CAS: 66575-29-9
客户使用Selleck的Forskolin (Colforsin)发表文献161篇
- Circulation, 2024 149(18):1435-1456
- Cell Stem Cell, 2024 S1934-5909(24)00048-1
- Cell Stem Cell, 2023 30(7):938-949.e7
- Nat Cell Biol, 2023 25(8):1223-1234
- Signal Transduct Target Ther, 2022 7(1):46
- Cell Stem Cell, 2022 29(8):1229-1245.e7
- Cell Discov, 2021 7(1):81
- Eur Respir J, 2021 2100908
- Nature, 2020 586(7827):101-107
- Cell Res, 2020 10.1038/s41422-020-0385-7
- Nat Mater, 2020 10.1038/s41563-020-00803-5
- Mil Med Res, 2020 7(1):52
- Mil Med Res, 2020 7(1):42
- Cell Res, 2019 29(12):1009-1026
- Nat Med, 2018 24(3):271-281
- Sci Bull (Beijing), 2024 S2095-9273(24)00799-0
- Cell Prolif, 2024 e13775.
- JCI Insight, 2024 9(24)e178535
- Elife, 2024 13RP97507
- J Transl Med, 2024 22(1):979
- iScience, 2024 27(2):108857
- Invest Ophthalmol Vis Sci, 2024 65(3):37
- Life Sci Alliance, 2024 7(6)e202302371
- Biology (Basel), 2024 13(9)684
- Cells Tissues Organs, 2024 1-14.
- Zhejiang Da Xue Xue Bao Yi Xue Ban, 2024 53(4):498-508
- Cell Rep Methods, 2024 4(11):100897
- bioRxiv, 2024 2024.01.15.574730
- ACS Cent Sci, 2023 9(4):719-732
- J Clin Invest, 2023 133(19)e163402
- Cell Rep Med, 2023 S2666-3791(23)00315-4
- Elife, 2023 12e83345
- Cell Death Discov, 2023 9(1):297
- Cells, 2023 12(13)1764
- iScience, 2023 26(3):106241
- iScience, 2023 26(11):108180
- iScience, 2023 26(12):108532
- Respir Res, 2023 24(1):217
- Am J Physiol Lung Cell Mol Physiol, 2023 324(6):L756-L770
- Viruses, 2023 15(7)1457
- Mol Biol Cell, 2023 34(8):ar79
- Sci Adv, 2023 9(10):eade8513
- J Vis Exp, 2023 (193).
- Nat Commun, 2022 13-1:6117
- Nat Commun, 2022 13(1):6497
- Nat Commun, 2022 13(1):3147
- Nat Commun, 2022 13(1):2256
- Adv Sci (Weinh), 2022 e2105568
- Nucleic Acids Res, 2022 gkac146
- Nat Protoc, 2022 10.1038/s41596-022-00742-2
- Nat Chem Biol, 2022 18(7):742-750
- Acta Pharm Sin B, 2022 12(2):787-800
- Theranostics, 2022 12(8):3847-3861
- Cell Death Differ, 2022 10.1038/s41418-022-01053-5
- Proc Natl Acad Sci U S A, 2022 119(20):e2115709119
- Cell Death Dis, 2022 13(5):493
- Cell Commun Signal, 2022 20(1):72
- J Tissue Eng, 2022 13:20417314221143240
- Elife, 2022 11e70341
- Transl Psychiatry, 2022 12(1):130
- Neural Regen Res, 2022 17(9):1867-1874
- Cells, 2022 11(15)2387
- iScience, 2022 25(11):105308
- Int J Mol Sci, 2022 23(8)4213
- Front Endocrinol (Lausanne), 2022 13:984081
- J Pers Med, 2022 12-91448
- Mol Ther Methods Clin Dev, 2022 24:11-19
- STAR Protoc, 2022 3(3):101638
- Nat Commun, 2021 12(1):3493
- Nat Commun, 2021 12(1):3332
- Adv Sci (Weinh), 2021 e2100190
- Cell Death Differ, 2021 10.1038/s41418-021-00897-7
- EMBO J, 2021 e105026
- Adv Healthc Mater, 2021 e2101580
- Int J Biol Sci, 2021 17(11):2756-2769
- Cell Death Dis, 2021 12(1):35
- Cell Rep, 2021 36(2):109360
- Cell Chem Biol, 2021 28(6):788-801.e5
- Cell Commun Signal, 2021 19(1):8
- Stem Cell Res Ther, 2021 12(1):269
- Free Radic Biol Med, 2021 163:220-233
- Front Pharmacol, 2021 12:592184
- Int J Mol Sci, 2021 22(19)10512
- Front Cell Dev Biol, 2021 9:722024
- Front Cell Dev Biol, 2021 9:728352
- Front Endocrinol (Lausanne), 2021 12:665145
- J Cyst Fibros, 2021 S1569-1993(21)01304-7
- Cell Signal, 2021 91:110226
- Molecules, 2021 26(19)5858
- Plants (Basel), 2021 11(1)62
- Sci Adv, 2021 7(33)eabf4416
- STAR Protoc, 2021 2(1):100346
- Autophagy, 2020 16(6):1061-1076
- Cancer Res, 2020 5 pii: canres
- Mol Psychiatry, 2020 10.1038/s41380-020-00866-5
- Cell Death Dis, 2020 6;11(4):221
- Cell Rep, 2020 33(11):108514
- Stem Cell Res Ther, 2020 11(1):415
- Cells, 2020 9(11)2422
- Cells, 2020 9(10)E2288
- Stem Cell Reports, 2020 15(2):408-423
- J Mol Cell Biol, 2020 30 pii: mjaa010
- Front Cell Neurosci, 2020 14:144
- Mol Cell Biol, 2020 40(4)
- J Biol Chem, 2020 14;jbcRA120013223
- Sci Rep, 2020 10(1):11828
- Sci Rep, 2020 28;10(1):7129
- Plants (Basel), 2020 9(12)E1672
- PLoS Genet, 2020 16(10):e1009100
- J Cell Sci, 2020 jcs.254268
- Exp Ther Med, 2020 20(3):2166-2172
- Physiol Rep, 2020 8(13):e14490
- Reprod Biol, 2020 10.1016
- Mol Ther, 2019 10.1016/j.ymthe.2019.08.011
- EMBO J, 2019 38(4)
- PLoS Biol, 2019 17(4):e3000228
- Cancer Lett, 2019 442:53-67
- Cell Rep, 2019 29(13):4256-4267.e9
- Cell Rep, 2019 29(7):1986-2000
- Mol Ther Nucleic Acids, 2019 16:73-81
- Biomed Pharmacother, 2019 121:109618
- Stem Cell Res Ther, 2019 10(1):364
- J Mater Chem B, 2019 7(47):7525-7539
- Transl Psychiatry, 2019 9(1):306
- Stem Cell Reports, 2019
- Int J Mol Sci, 2019 20(17)
- Sci Rep, 2019 9(1):10828
- Exp Ther Med, 2019 17(5):3573-3579
- Am J Transl Res, 2019 11(8):5122-5133
- Clin Cancer Res, 2018 10.1158/1078-0432.CCR-18-2912
- J Exp Clin Cancer Res, 2018 37(1):288
- J Exp Clin Cancer Res, 2018 37(1):114
- Am J Hum Genet, 2018 102(6):1062-1077
- Sci China Life Sci, 2018 10.1007/s11427-018-9359-8
- Cell Death Dis, 2018 9(7):747
- Oncogene, 2018 37(22):2953-2966
- JCI Insight, 2018 3(14)
- EMBO Rep, 2018 19(2):320-336
- Front Pharmacol, 2018 9:1176
- J Virol, 2018 92(20)
- PLoS Genet, 2018 14(11):e1007723
- Cell Physiol Biochem, 2018 45(3):1023-1033
- Reprod Domest Anim, 2018 10.1111/rda.13304
- Dev Cell, 2017 43(6):673-688
- Cell Rep, 2017 18(2):468-481
- Oncogene, 2017 36(41):5668-5680
- Osteoarthritis Cartilage, 2017 25(11):1868-1879
- Oncotarget, 2017 8(36):60135-60148
- Mol Cancer Res, 2017 15(12):1792-1802
- PLoS One, 2017 12(3):e0173240
- Gen Comp Endocrinol, 2017 240:191-197
- Oncogene, 2016 35(38):5070-7
- Sci Signal, 2016 9(430):ra56
- J Cyst Fibros, 2016 15(3):285-94
- Sci Rep, 2016 6:26835
- Development, 2016 143(12):2103-10
- Sci Rep, 2016 6:36661
- Gen Comp Endocrinol, 2016 237:98-108
- J Biol Chem, 2015 290(50):30030-41
- Toxicol Appl Pharmacol, 2015 289(1):109-16
- Eur J Cancer, 2014 50(7):1310-20
化学信息&溶解度
分子量 | 410.5 |
分子式 | C22H34O7 |
CAS号 | 66575-29-9 |
Smiles | CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O |
储存条件(自收到货起) | 3年 -20°C(避光) 粉状 1年 -80°C(避光) 溶于溶剂 |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 40 mg/mL ( 97.44 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 20 mg/mL Water : Insoluble DMSO : 82 mg/mL ( 199.75 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 82 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:1.05mg/ml
(2.56mM)
操作示例:以 1 mL 工作液为例,取50μL21mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。